100 related articles for article (PubMed ID: 10616934)
21. Challenges in the treatment of dysthymia: a narrative review.
Mathias L; Quagliato LA; Carta MG; Nardi AE; Cheniaux E
Expert Rev Neurother; 2024 Jul; 24(7):633-642. PubMed ID: 38805342
[TBL] [Abstract][Full Text] [Related]
22. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants.
Mukai Y; Tampi RR
Clin Ther; 2009 May; 31(5):945-61. PubMed ID: 19539096
[TBL] [Abstract][Full Text] [Related]
23. A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes.
Rocca P; Marchiaro L; Rasetti R; Rivoira E; Bogetto F
Psychiatry Res; 2002 Oct; 112(2):145-52. PubMed ID: 12429360
[TBL] [Abstract][Full Text] [Related]
24. Recognition and treatment of dysthymia in elderly patients.
Bellino S; Bogetto F; Vaschetto P; Ziero S; Ravizza L
Drugs Aging; 2000 Feb; 16(2):107-21. PubMed ID: 10755327
[TBL] [Abstract][Full Text] [Related]
25. Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults.
Williams JW; Barrett J; Oxman T; Frank E; Katon W; Sullivan M; Cornell J; Sengupta A
JAMA; 2000 Sep; 284(12):1519-26. PubMed ID: 11000645
[TBL] [Abstract][Full Text] [Related]
26. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2012 Apr; 66(4):356-68. PubMed ID: 22284853
[TBL] [Abstract][Full Text] [Related]
27. Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study.
Hellerstein DJ; Hunnicutt-Ferguson K; Stewart JW; McGrath PJ; Keller S; Peterson BS; Chen Y
J Affect Disord; 2017 Mar; 210():258-264. PubMed ID: 28064115
[TBL] [Abstract][Full Text] [Related]
28. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years.
Barrett JE; Williams JW; Oxman TE; Frank E; Katon W; Sullivan M; Hegel MT; Cornell JE; Sengupta AS
J Fam Pract; 2001 May; 50(5):405-12. PubMed ID: 11350703
[TBL] [Abstract][Full Text] [Related]
29. WITHDRAWN: Drugs versus placebo for dysthymia.
Silva de Lima M; Moncrieff J; Soares BG
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD001130. PubMed ID: 26087170
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
[TBL] [Abstract][Full Text] [Related]
31. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
[TBL] [Abstract][Full Text] [Related]
32. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy.
Pinquart M; Duberstein PR; Lyness JM
Am J Psychiatry; 2006 Sep; 163(9):1493-501. PubMed ID: 16946172
[TBL] [Abstract][Full Text] [Related]
33. Antidepressant use in nonmajor depression: secondary analysis of a program to encourage active, rewarding lives for seniors (PEARLS), a randomized controlled trial in older adults from 2000 to 2003.
Lakey SL; Gray SL; Ciechanowski P; Schwartz S; Logerfo J
Am J Geriatr Pharmacother; 2008 Mar; 6(1):12-20. PubMed ID: 18396244
[TBL] [Abstract][Full Text] [Related]
34. Tachyphylaxis/tolerance to antidepressants in treatment of dysthymia: results of a retrospective naturalistic chart review study.
Katz G
Psychiatry Clin Neurosci; 2011 Aug; 65(5):499-504. PubMed ID: 21851459
[TBL] [Abstract][Full Text] [Related]
35. [Subaffective disorders: dysthymia and cyclothymia].
Brieger P
MMW Fortschr Med; 2010 Jan; 152(3):31-3. PubMed ID: 20333963
[No Abstract] [Full Text] [Related]
36. Psychotherapy for chronic major depression and dysthymia: a meta-analysis.
Cuijpers P; van Straten A; Schuurmans J; van Oppen P; Hollon SD; Andersson G
Clin Psychol Rev; 2010 Feb; 30(1):51-62. PubMed ID: 19781837
[TBL] [Abstract][Full Text] [Related]
37. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients.
McLeod MN; Gaynes BN; Golden RN
J Clin Psychiatry; 1999 Apr; 60(4):237-40. PubMed ID: 10221284
[TBL] [Abstract][Full Text] [Related]
38. Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder.
Carta MG; Paribello P; Nardi AE; Preti A
Expert Opin Pharmacother; 2019 Oct; 20(14):1743-1754. PubMed ID: 31290333
[No Abstract] [Full Text] [Related]
39. Advantages and limitations of the concept of antidepressant therapy.
Freeman HL
Eur Neuropsychopharmacol; 1997 Oct; 7 Suppl 3():S315-21. PubMed ID: 9405957
[TBL] [Abstract][Full Text] [Related]
40. Pharmacotherapy of dysthymia: review and new findings.
Versiani M; Nardi AE; Figueira I
Eur Psychiatry; 1998 Jul; 13(4):203-9. PubMed ID: 19698626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
